

Scientific program

Monday May 14th

08:30 Welcome. ECCL and Partners.

08:30 ECCL : mission and activities.

Arnaud MARCHANT, Belgium

08:40 Partnership with ESCV.

Pamela VALLELY, UK

08:50 Global CMV Network.

Laura GIBSON, USA

09:00 Presentation by patient groups • Anne-Hélène LABISSY, France; Francesca LOVATO, Italy; Elizaveta PADALKO, Belgium

09:20 Burden of congenital CMV infection • Chairs: Graciela ANDREI, Belgium; Paulo PAIXÃO, Portugal

09:20 CMV, pregnancy, ethics : the links ?

Luc ROEGIERS, Belgium

09:45 Risk perception and recourse to pregnancy termination due to maternal cytomegalovirus infection.

Annalisa CARAPEZZI, Italy

10:00 Coffee break

10:30 Burden of congenital CMV infection (Part 2) • Chairs: Graciela ANDREI, Belgium; Paulo PAIXÃO, Portugal

10:30 Health and economic burden of congenital CMV infection in Europe.

Suzanne SMIT, Belgium

10:55 The economic cost of congenital CMV in the UK.

Sharon WOOD, UK

11:10 Worldwide cytomegalovirus seroprevalence: a systematic review and meta-analysis.

Mohamed ZUHAIR, UK

11:25 Diagnosis of maternal, fetal and neonatal infections • Chairs: Jos VAN ACKER, Belgium; Theresia POPOW-KRAUPP, Austria; Tiziana LAZZAROTTO, Italy

11:25 Diagnosis of maternal infection.

Marianne LERUEZ-VILLE, France

11:50 Combination of line immunoassays Mikrogen recomLine CMV IgG and recomLine CMV IgG avidity helps to date the onset of CMV primary infection.

Marie-Luce DELFORGE, Belgium

12:05 Kinetics of human cytomegalovirus IgG avidity maturation: a serological marker of vertical transmission.

Milena FURIONE, Italy

12:20 Correlation between type of maternal CMV infection (primary versus non-primary) and outcome. A systematic review and Incidence of SNHL in infants born post maternal non-primary CMV infection. Implications for routine maternal prenatal screening.

Vassiliki PAPAEVANGELOU, Greece

12:40 Lunch and posters

14:10 Diagnosis of maternal, fetal and neonatal infections (Part 2) • Chairs: Jos VAN ACKER, Belgium; Theresia POPOW-KRAUPP, Austria; Tiziana LAZZAROTTO, Italy

14:10 Diagnosis of fetal and neonatal infections.

Pamela VALLELY, UK

14:35 Comparative study of 2 screening techniques for cCMV infection: viral isolation in urine and PCR for CMV on the Guthrie card.

Annelies KEYMEULEN, Belgium

14:50 PICCSA Study. Prevalence and clinical manifestations of congenital cytomegalovirus infection in a screening program in Madrid.

Daniel BLÁZQUEZ-GAMERO, Spain

15:05 Treatment and prognosis of fetal and paediatric infections • Chairs: Catherine DONNER, Belgium; Giuliana SIMONAZZI, Italy; Dana WOLF, Israel

15:05 Treatment and prognosis of fetal infection.

Yves VILLE, France

15:30 New insights into the pathophysiology of hyperechogenic bowel in CMV infected fetuses.

Liliana GABRIELLY, Italy

15:45 Predictive value of blood parameters in cytomegalovirus (CMV) infected fetuses with sonographic findings according to the trimester of pregnancy at cordocentesis.

Anna GONCE, Spain

16:00 Fetal treatment for congenital cytomegalovirus infection: Study of the placental transfer of Letemovir in the ex vivo human cotyledon perfusion model.

Valentine FAURE-BARDON, France

16:15 Coffee Break

16:45 Treatment and prognosis of fetal and paediatric infections (Part 2) • Chairs: Catherine DONNER, Belgium; Giuliana SIMONAZZI, Italy; Dana WOLF, Israel

16:45 Treatment and prognosis of paediatric infection.

Suzanne LUCK, UK

17:10 Evaluation of cell mediated immunity (CMI) using the QuantiFERON-CMV test in congenital CMV infection (cCMV).

Concetta MARSICO, Italy

17:25 Prognostic value of magnetic resonance imaging in newborns with congenital cytomegalovirus infection.

Daniel BLÁZQUEZ-GAMERO, Spain

17:40 The role of CMV-DNA detection in cerebro-spinal fluid in newborns with congenital CMV infection: a 6-year experience of a tertiary care neonatal center.

Justyna CZECH-KOWALSKA, Poland

17:55 Valnoctamide rescues CMV-induced deafness in a murine model.

Sara ORNAGHI, Italy and USA

18:10 Management of congenital CMV-Infection: Updated recommendations in Germany.

Susanne MODROW, Germany

18:25 End of session

20:00 Dinner in town

Tuesday May 15th

08:30 Prevention of maternal infection and of vertical transmission • Chairs: Pascale HUYNEN, Belgium; Arnaud MARCHANT, Belgium; Corinne HUBINONT, Belgium

08:30 Prevention of maternal infection and of vertical transmission.

Paul GRIFFITHS, UK

08:55 Development of a digital antenatal educational intervention to reduce the risk of acquisition of CMV in pregnancy: Working in partnership with pregnant women and families affected by CMV.

Christine JONES, UK

09:10 A multiparametric approach to identify specific immune profiles controlling HCMV vertical transmission from primary infected pregnant women.

Fabienne PIRAS-DOUCE, France

09:25 CMV vaccines, an update.

Ben VAN DER ZEIJST, The Netherlands

09:50 A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

Miriam REUSCHENBACH, Germany

10:05 HCMV receptors identification by unbiased screening.

Laurent PEREZ, Switzerland

10:20 Coffee break

10:50 Prevention of maternal infection and of vertical transmission (part 2) • Chairs: Pascale HUYNEN, Belgium; Arnaud MARCHANT, Belgium; Corinne HUBINONT, Belgium

10:50 Towards the development of antibody-based immunoprophylaxis of congenital CMV infection.

Michael SCHMID, Switzerland

11:15 Impact of pharmacokinetics on the HIG efficiency to prevent maternofetal CMV transmission.

Klaus HAMPRECHT, Germany

11:30 Changed expression of angiogenic factors following HCMV-vertical transmission - Results from serum and amniotic fluid samples.

Lukas Edgar Maximilien PENKA, Germany

11:45 Lunch and posters

13:15 Clinical and epidemiological studies and clinical registries in Europe • Chairs: Ina FOULON, Belgium; Vana PAPADEVANGELOU, Greece

13:15 Introduction. Mapping the congenital CMV related clinical and epidemiological research capacity in Europe.

Suzanne SMIT, Belgium

13:30 The CROCUS study (Consequences and Risk factors Of congenital Cytomegalovirus): the

strengths and limitations of this retrospective cohort study.

Ann VOSSSEN, The Netherlands

13:45 Congenital CMV in France, databases, epidemiology and practices.

Sophie ALAIN, France

14:00 Hearing loss in children with a congenital cytomegalovirus infection: a 22-year survey.

Ina FOULON, Belgium

14:15 Epidemiology and prevention of non-primary human cytomegalovirus infection in pregnancy (CHILd study).

Daniele LILLERI, Italy

14:30 Introduction. Registries in Europe and the Spanish experience.

Daniel BLÁZQUEZ-GAMERO, Spain

14:45 ECCL registry: Together we rule.

Suzanne LUCK, UK

15:00 COIN Project: Standardising outcomes to reduce research waste.

James WEBBE, UK

15:15 Conducting a registry for children with congenital cytomegalovirus infection in Flanders: results, strengths and limitations.

Annelies KEYMEULEN, Belgium

15:30 Panel discussion. The future of congenital CMV research in Europe. • Arnaud MARCHANT, Belgium; Pamela VALLELY, UK; Elizaveta PADALKO, Belgium

16:30 End of meeting
